Morgan Stanley Maintains Their Buy Rating on Insmed (INSM)


Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Insmed (NASDAQ: INSM) today and set a price target of $39. The company’s shares closed on Friday at $26.15.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 14.2% and a 63.4% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Sarepta Therapeutics, and Editas Medicine Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insmed with a $40.50 average price target, a 54.9% upside from current levels. In a report issued on August 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $35 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $33.94 and a one-year low of $11.49. Currently, Insmed has an average volume of 689.1K.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Orlov Nicole Schaeffer, the Chief People Strategy Officer of INSM sold 37,575 shares for a total of $1,054,631.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. It focuses on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded on November 29, 1999 and is headquartered in Bridgewater, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts